Table 3 Patient profiles showing presence or absence of clinical presentations and gene mutations
From: Proto-oncogene mutations in middle ear cholesteatoma contribute to its pathogenesis
Patient | age | analysis | type | stage | ossicles destruction | Granulation | dura exposure | Facial nerve exposure | Labilynthin fistura | Facial palsy | variants |
|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 38 | exome | PF | II | < 50% | + | + | – | – | – | myc |
3 | 17 | exome | PF | Ib | < 50 | – | – | – | – | – | |
4 | 57 | exome | PF | II | > 50 | + | + | + | – | – | Notch |
5 | 73 | exome | PT | II | > 50 | – | – | + | – | – | Notch |
6 | 54 | exome | PF | II | < 50 | – | – | – | – | – | |
7 | 28 | Taget capture | PF | II | < 50 | + | – | – | – | – | |
8 | 59 | Taget capture | PF | III LF | < 50 | + | + | + | + | – | Myc |
9 | 49 | Taget capture | PF | II | < 50 | + | + | + | – | – | |
10 | 41 | Taget capture | PF | II | < 50 | + | – | – | – | – | |
11 | 49 | Taget capture | R | > 50 | + | + | – | – | – | ||
12 | 64 | Taget capture | R | < 50 | – | – | – | – | – | Notch | |
13 | 73 | Taget capture | secondary | II | < 50 | + | – | + | – | – | |
14 | 29 | Taget capture | PF | III LF | > 50 | + | + | + | + | – | |
15 | 64 | Taget capture | PF | III LF | > 50 | + | + | + | + | – | Notch |
16 | 57 | Taget capture | C | III FP | < 50 | – | + | + | + | + | |
17 | 60 | Taget capture | secondary | II | < 50 | + | – | – | – | – | |
18 | 74 | Taget capture | PT | Ia | < 50 | – | – | – | – | – | Notch |
19 | 33 | Taget capture | PF | Ib | < 50 | + | – | – | – | – | |
21 | 56 | Taget capture | PF | Ib | < 50 | – | – | – | – | – | |
24 | 5 | Taget capture | PF | II | < 50 | – | – | – | – | – | |
25 | 17 | Taget capture | R | – | – | – | – | – | |||
26 | 6 | Taget capture | PF | II | < 50 | + | – | – | – | – |